Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer

Author(s): Shigehiro Yagishita and Akinobu Hamada

Volume 15, Issue 14, 2014

Page: [1263 - 1272] Pages: 10

DOI: 10.2174/1389450115666141110154838

Price: $65


Development of molecular targeting agents, starting with imatinib for chronic myeloid leukemia or gefitinib for non-small cell lung cancer (NSCLC), has recently progressed at a rapid rate. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have already been developed to the 2nd and 3rd generation, and novel drug development targeted towards Met activation, which is an EGFR-TKI resistance mechanism, is ongoing. Although the era of new anticancer agents is moving towards an era of molecular targeting agents, the methods used for drug development are not different than before. In addition to the importance of pharmacokinetics (PK) and pharmacodynamics (PD) for drug development, emerging evidence is also demonstrating the significance of pharmacogenomics, since certain types of gene alteration may greatly affect drug metabolism, excretion, and notably, clinical efficacy. It is desirable to determine optimal doses of anticancer drugs by taking into account these factors that could potentially influence PK/PD. The following article reviews the clinical development of EGFR/Met inhibitors for NSCLC and the clinical pharmacology of these drugs.

Keywords: Epidermal growth factor receptor, Met, non-small cell lung cancer, pharmacology.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy